Prognostic significance of severe coronary microvascular dysfunction post-PCI in patients with STEMI: A systematic review and meta-analysis.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 29 09 2021
accepted: 27 04 2022
entrez: 16 5 2022
pubmed: 17 5 2022
medline: 20 5 2022
Statut: epublish

Résumé

Coronary microvascular dysfunction (CMVD) is common and associated with poorer outcomes in patients with ST Segment Elevation Myocardial Infarction (STEMI). The index of microcirculatory resistance (IMR) and the index of hyperemic microvascular resistance (HMR) are both invasive indexes of microvascular resistance proposed for the diagnosis of severe CMVD after primary percutaneous coronary intervention (pPCI). However, these indexes are not routinely assessed in STEMI patients. Our main objective was to clarify the association between IMR or HMR and long-term major adverse cardiovascular events (MACE), through a systematic review and meta-analysis of observational studies. We searched Medline, PubMed, and Google Scholar for studies published in English until December 2020. The primary outcome was a composite of cardiovascular death, non-cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and rehospitalization for heart failure occurring after at least 6 months following CMVD assessment. We identified 6 studies, reporting outcomes in 1094 patients (mean age 59.7 ± 11.4 years; 18.2% of patients were women) followed-up from 6 months to 7 years. Severe CMVD, defined as IMR > 40 mmHg or HMR > 3mmHg/cm/sec was associated with MACE with a pooled HR of 3.42 [2.45; 4.79]. Severe CMVD is associated with an increased risk of long-term adverse cardiovascular events in patients with STEMI. Our results suggest that IMR and HMR are useful for the early identification of severe CMVD in patients with STEMI after PCI, and represent powerful prognostic assessments as well as new therapeutic targets for clinical intervention.

Identifiants

pubmed: 35576227
doi: 10.1371/journal.pone.0268330
pii: PONE-D-21-31414
pmc: PMC9109915
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0268330

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS One. 2016 Jul 08;11(7):e0157233
pubmed: 27391645
Circ Cardiovasc Interv. 2017 Dec;10(12):
pubmed: 29222132
BMJ. 2019 Jan 30;364:k4597
pubmed: 30700442
Am J Cardiol. 2018 Jan 1;121(1):1-8
pubmed: 29132649
JCI Insight. 2016 May 5;1(6):e85768
pubmed: 27699259
Eur Heart J. 2004 Feb;25(3):219-23
pubmed: 14972422
Am J Cardiol. 2008 Jul 15;102(2):129-34
pubmed: 18602508
Ann Intern Med. 2013 Feb 19;158(4):280-6
pubmed: 23420236
Circulation. 2006 May 2;113(17):2054-61
pubmed: 16636168
Circ Cardiovasc Interv. 2014 Apr;7(2):149-55
pubmed: 24550440
Circulation. 2001 Oct 23;104(17):2003-6
pubmed: 11673336
Int J Cardiol. 2016 Jan 1;202:305-10
pubmed: 26418191
JACC Cardiovasc Interv. 2016 Oct 24;9(20):2172-2174
pubmed: 27765315
Trials. 2007 Jun 07;8:16
pubmed: 17555582
Eur Heart J. 2009 Dec;30(23):2854-60
pubmed: 19684025
Eur Heart J. 2016 Apr 1;37(13):1024-33
pubmed: 26364289
Circulation. 2002 May 28;105(21):2482-6
pubmed: 12034653
Heart. 2018 Jan;104(2):127-134
pubmed: 28663361
JACC Cardiovasc Interv. 2019 May 27;12(10):951-966
pubmed: 31122353
Circ Cardiovasc Interv. 2020 May;13(5):e008505
pubmed: 32408817
Circulation. 2004 Mar 9;109(9):1121-6
pubmed: 14967718
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
Korean Circ J. 2015 May;45(3):194-201
pubmed: 26023307
J Am Coll Cardiol. 2008 Feb 5;51(5):560-5
pubmed: 18237685
Circulation. 2016 Dec 6;134(23):1833-1847
pubmed: 27803036
Circulation. 2013 Jun 18;127(24):2436-41
pubmed: 23681066
Cardiovasc Res. 2020 Mar 1;116(4):787-805
pubmed: 31710673
Syst Rev. 2013 Sep 05;2:71
pubmed: 24007720
JACC Cardiovasc Imaging. 2019 May;12(5):837-848
pubmed: 29680355
Circ Cardiovasc Interv. 2015 Mar;8(3):e001786
pubmed: 25717044
Eur Heart J. 2017 Dec 14;38(47):3502-3510
pubmed: 29020248
JACC Cardiovasc Interv. 2010 Jul;3(7):715-22
pubmed: 20650433

Auteurs

Marjorie Canu (M)

Department of Cardiology, University Hospital, Grenoble-Alpes, France.

Charles Khouri (C)

INSERM U1042, HP2 Laboratory, University Grenoble-Alps, Grenoble, France.
Clinical Pharmacology Department, INSERM CIC1406, University Hospital, Grenoble, France.

Stéphanie Marliere (S)

Department of Cardiology, University Hospital, Grenoble-Alpes, France.

Estelle Vautrin (E)

Department of Cardiology, University Hospital, Grenoble-Alpes, France.

Nicolas Piliero (N)

Department of Cardiology, University Hospital, Grenoble-Alpes, France.

Olivier Ormezzano (O)

Department of Cardiology, University Hospital, Grenoble-Alpes, France.
INSERM U1039, Bioclinic Radiopharmaceutics Laboratory, Grenoble, France.

Bernard Bertrand (B)

Department of Cardiology, University Hospital, Grenoble-Alpes, France.

Hélène Bouvaist (H)

Department of Cardiology, University Hospital, Grenoble-Alpes, France.

Laurent Riou (L)

INSERM U1039, Bioclinic Radiopharmaceutics Laboratory, Grenoble, France.

Loic Djaileb (L)

INSERM U1039, Bioclinic Radiopharmaceutics Laboratory, Grenoble, France.

Clémence Charlon (C)

Department of Cardiology, University Hospital, Grenoble-Alpes, France.
INSERM U1039, Bioclinic Radiopharmaceutics Laboratory, Grenoble, France.

Gerald Vanzetto (G)

Department of Cardiology, University Hospital, Grenoble-Alpes, France.
INSERM U1039, Bioclinic Radiopharmaceutics Laboratory, Grenoble, France.
French Clinical Research Infrastructure Network, Paris, France.

Matthieu Roustit (M)

INSERM U1042, HP2 Laboratory, University Grenoble-Alps, Grenoble, France.
Clinical Pharmacology Department, INSERM CIC1406, University Hospital, Grenoble, France.

Gilles Barone-Rochette (G)

Department of Cardiology, University Hospital, Grenoble-Alpes, France.
INSERM U1039, Bioclinic Radiopharmaceutics Laboratory, Grenoble, France.
French Clinical Research Infrastructure Network, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH